Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32

Author: Benzinga Newsdesk | October 15, 2025 07:44am
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises the price target from $29 to $32.

Posted In: APLS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist